Global Electrolyte and Biochemistry Analyzers Market 2021 Segmentation, Strategy, Share, Growth Factors, Analysis and Forecast to 2026 The Manomet…

June 21, 2021 medical

Global Electrolyte and Biochemistry Analyzers Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 introduced by MarketQuest.biz contains a carefully investigated comprehensive and professional market research study that begins with a market overview and moves on to cover the growth prospects of the market during the 2021 to 2026 time period. The report focuses on top players and their business strategies, geographical extension, market segments, competitive landscape, assembling, and evaluating and cost structures. The report offers the current state of the market around the world. The report starts with the market outline and key components of the global Electrolyte and Biochemistry Analyzers market.

The report offers the key focuses to upgrade the development in the market. Some fundamental ideas are likewise presented by reports, for example, item definition, its application, industry esteem chain structure. The report covers data relevant to new market entrants or established players. Furthermore, details of well-established contenders functioning in the global Electrolyte and Biochemistry Analyzers market along with their product/service contributions, manufacturing process, income details, capacity, new product launches, acquisitions, partnership, and business synopsis are given in this report.

NOTE: Consumer behaviour has changed within all sectors of the society amid the COVID-19 pandemic. Industries on the other hand will have to restructure their strategies in order to adjust with the changing market requirements. This report offers you an analysis of the COVID-19 impact on the Electrolyte and Biochemistry Analyzers market and will help you in strategising your business as per the new industry norms.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/51923

The report also presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market:

Roche, Danaher, Siemens, Abbott, Hitachi, Horiba Medical, Mindray, ThermoFisher, Shanghai Kehua Bio-Engineering Co., Ltd, Senlo, Sunostik, ELITec Group, Sysmex, Jiangxi TECom, URIT Medical Electronic, Randox Laboratories, Dirui, Shenzhen Rayto, Convergent Technologies, Meizhou Cornley, Diestro, Caretium, Erba Mannheim, Hycel Medical, Idexx Laboratories, Nova Biomedical, SFRI, Medica, Shenzhen Genius Biotech Inc, Sensa Core

Each part of the analysis study is extraordinarily set up to investigate key aspects of the worldwide Electrolyte and Biochemistry Analyzers market. The market elements segment dives profound into the drivers, restraints, trends, and opportunities of the market. The study comprises primary information about the products. It also includes raw materials used and the manufacturing process of the market. The business chain structure records significant players, cost structure, material analysis, work costs, promoting channels, and downstream investigations.

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into:

Electrolyte Analyzers, Biochemistry Analyzers

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share, and growth rate for each application, including :

Hospital, Clinic, Labs, Others

Geographically, the following regions together with the listed:

North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia), South America (Brazil, Argentina, Colombia, and Rest of South America), Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

ACCESS FULL REPORT: https://www.marketquest.biz/report/51923/global-electrolyte-and-biochemistry-analyzers-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026

Key Questions Answered In The Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketquest.bizWeb: http://www.marketquest.biz

See more here:
Global Electrolyte and Biochemistry Analyzers Market 2021 Segmentation, Strategy, Share, Growth Factors, Analysis and Forecast to 2026 The Manomet...

Biochemistry

Craig Lindsley named to Medicinal Chemistry Division of the American Chemical Society Hall of Fame – Vanderbilt University News

June 21, 2021 medical

Craig Lindsley, the William K. Warren, Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry

Craig Lindsley, the William K. Warren, Jr. Chair in Medicine and director of Vanderbilt Universitys Warren Center for Neuroscience Drug Discovery, will be inducted as a member of the 2021 class of theDivision of Medicinal Chemistry Hall of Fame. MEDI is a subunit of theAmerican Chemical Society, the worlds largest scientific society and the premier home ofchemistryprofessionals.

Lindsley, the youngest inductee to the Hall of Fame, was selected because of his contributions to the field of medicinal chemistry.

This is a huge, career-defining honor and an amazing group of medicinal chemists and drug discovery scientists amongst whom to be included. This is a tremendous acknowledgement of the WCNDDs work and influence in the medicinal chemistry field, said Lindsley, also University Professor of Pharmacology, Biochemistry and Chemistry. In all honesty, this honor belongs to all of my former and current colleagues from Lilly, Merck and the WCNDD. Medicinal chemistry is just one arm of successful drug discovery, and no one person can do this alone or take creditit is big team science.

Craig Lindsley is a great medicinal chemist whose impact has been recognized not only by his induction into the MEDI Hall of Fame but also by his recent appointment as editor in chief of theJournal of Medicinal Chemistry, the premier journal in the field, saidLawrence Marnett, dean of the School of Medicine Basic Sciences. He brings great credit to the Basic Sciences and to Vanderbilt, but his greatest legacy may be the contributions he is making to improving the lives of individuals suffering from neurological diseases and neuropsychiatric disorders.

Induction into the ACS Division of Medicinal Chemistry Hall of Fame is an acknowledgement by leaders in our field that an individual scientist has had a sustained and substantial impact on research, teaching or service to the division, saidJacob Schwarz, chair of the ACS Division of Medicinal Chemistry executive committee. Dr. Lindsley is a rare example of someone who embodies all three of these achievements: from his early career work in the pharmaceutical industry, to his current role as educator and research mentor and finally as an ad hoc member of the MEDI executive committee. Dr. Lindsley has become well-known in our scientific community thanks to his tireless efforts both as author and editor, advancing the field of neuroscience drug discovery through research and training and by being an active social media presence highlighting exciting new developments.

Other 2021 MEDI Hall of Fame inductees areEdward Roberts, professor of molecular medicine and Scripps Research, andAnabella Villalobos, medicinal chemist and senior pharmaceutical executive at Biogen. Inductees are selected annually from nominations submitted by MEDI members and who have previously received theEdward E.Smissman Award, theDivision of Medicinal Chemistry award, an ACSGlaxoSmithKline Alfred Burger Awardor anE. B. Hershberg Award.

The 2021 Hall of Fame inductees will be recognized at the ACS National Meeting in Atlanta on Aug. 22, 2021.

Original post:
Craig Lindsley named to Medicinal Chemistry Division of the American Chemical Society Hall of Fame - Vanderbilt University News

Biochemistry

Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome – Science Magazine

June 21, 2021 medical

Severe acute respiratory syndrome coronavirus 2 critically depends on the ribosomal frameshifting that occurs between two large open reading frames in its genomic RNA for expression of viral replicase. Programmed frameshifting occurs during translation, when the ribosome encounters a stimulatory pseudoknot RNA fold. Using a combination of cryoelectron microscopy and biochemistry, Bhatt et al. revealed that the pseudoknot resists unfolding as it lodges at the entry of the ribosomal messenger RNA channel. This causes back slippage of the viral RNA, resulting in a minus-1 shift of the reading frame of translation. A partially folded nascent viral polyprotein forms specific interactions inside the ribosomal tunnel that can influence the efficiency of frameshifting.

Science, abf3546, this issue p. 1306

See more here:
Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome - Science Magazine

Biochemistry

Metabolomics Reagents Market to Witness Robust Expansion by 2028 with Top Key players like Kerafast, Nitto Boseki, BD, Beijing Leadman Biochemistry …

June 21, 2021 medical

The report scope furnishes vital statistics about the current Metabolomics Reagents market status and key companies. It analyzes the in-depth business by considering different aspects, directions for companies, and strategies in the industry. After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered.The report also summarizes the various types of Metabolomics Reagents Market factors that influence the market growth of particular product category type and market status for it. A detailed study of the Metabolomics Reagents Market has been done to understand the various applications of the usage and features of the product. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

The report additionally provides a PESTEL analysis along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Metabolomics Reagents market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

Top Key Companies:Kerafast, Nitto Boseki, BD, Beijing Leadman Biochemistry, Beijing Strong Biotechnologies, Randox Laboratories Limited, Biosino, Luxcel Biosciences, Shenzhen Bioeasy Biotechnology, Pointe Scientific, Biovision, Abbott, Shenzhen Lvshiyuan Biotechnology, Thermo Fisher Scientific, Merck[PDF] Get Latest Sample Report of Global Metabolomics ReagentsMarket 2021-2028: https://www.lexisbusinessinsights.com/request-sample-220167

The report has segmented Market 2021?2028 into different components on the basis of products, Application, geography and end users wherever needed. With thorough analysis and detailed study of past, present and future market 2017?2028 conditions, the report is able to deliver factual and reliable information to the users.

By Region / Countries

Key questions answered in the report include:

Our Research Experts have made this insightful report on Metabolomics Reagentsmarket, which is available for user on the site of Market Research Vision. The report carries various factors and elements of the industry in picture, all around the globe, be it its potential or probable threat to its growth or simply the way and method of its functioning during covid-19.

Reasons for Buying this Report:

TABLE OF CONTENT:

1 Report Overview

2 Global Metabolomics Reagents Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2015-2028

14 Analyst?s Viewpoints/Conclusions

15 Appendix

Feel free with your queries to get a call from our research expert @ https://www.lexisbusinessinsights.com/request-sample-220167

About Lexis Business Insights Market Research:

Lexis Business Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SME?s, start-ups, financial technology start-ups, and venture capitalists. We have an exhaustive database of market research reports provided by more than 20 leading publishers across different industry verticals.

We provide tailored solutions that can be utilized to solve business challenges and problems faced by organizations in different regions. Additionally, our bouquet of solutions assists enterprises in strategic planning and staying ahead of the competition while getting access to extensive market forecast and trend mapping over the future course of time. In addition to the market forecast and other vital components of the market analysis, our reports include in-depth micro-macro analysis of the market, which aids the customers in analyzing the market ecosystem, thus assisting in the existing and new players in the development of strategic plans.Contact Us:James(Key Account Manager)

US: +1 210 907 4145

6851 N Loop

1604 W San Antonio,

TX 78249

sales@lexisbusinessinsights.com

http://www.lexisbusinessinsights.com

Visit link:
Metabolomics Reagents Market to Witness Robust Expansion by 2028 with Top Key players like Kerafast, Nitto Boseki, BD, Beijing Leadman Biochemistry ...

Cell Biology

Who’s to Die and Who’s to Live: Mechanical Cue Is at the Origin of Cell Death Decision – SciTechDaily

June 5, 2021 medical

In many species including humans, the cells responsible for reproduction, the germ cells, are often highly interconnected and share their cytoplasm. In the hermaphrodite nematode Caenorhabditis elegans, up to 500 germ cells are connected to each other in the gonad, the tissue that produces eggs and sperm. These cells are arranged around a central cytoplasmic corridor and exchange cytoplasmic material fostering cell growth, and ultimately produce oocytes ready to be fertilized.

In past studies, researchers have found that C. elegans gonads generate more germ cells than needed and that only half of them grow to become oocytes, while the rest shrinks and die by physiological apoptosis, a programmed cell death that occurs in multicellular organisms. Now, scientists from the Biotechnology Center of the TU Dresden (BIOTEC), the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), the Cluster of Excellence Physics of Life (PoL) at the TU Dresden, the Max Planck Institute for the Physics of Complex Systems (MPI-PKS), the Flatiron Institute, NY, and the University of California, Berkeley, found evidence to answer the question of what triggers this cell fate decision between life and death in the germline.

Hydraulic instabilities dictate the volumes of germ cells and balloons Left: Picture of two balloons connected through a central tube, any new air coming through the white pipe will inflate the red balloon rather than the blue one. Right: Spinning-disk confocal image of interconnected C. elegans germ cells. Cortical actin showing the cell cortex is labelled in magenta and myosin, delineating the germ cells openings through which both cells exchange cytoplasmic material, is labelled in green. Credit: TU Dresden

Prior studies revealed the genetic basis and biochemical signals that drive physiological cell death, but the mechanisms that select and initiate apoptosis in individual germ cells remained unclear. As germ cells mature along the gonad of the nematode, they first collectively grow in size and in volume homogenously. In the study just published in Nature Physics, the scientists show that this homogenous growth suddenly shifts to a heterogenous growth where some cells become bigger and some cells become smaller.

The researcher Nicolas Chartier in the group of Stephan Grill, and co-first author of the study, explains: By precisely analyzing germ cell volumes and cytoplasmic material fluxes in living worms and by developing theoretical modeling, we have identified a hydraulic instability that amplifies small initial random volume differences, which causes some germ cells to increase in volume at the expense of the others that shrink. It is a phenomenon, which can be compared to the two-balloon instability, well known of physicists. Such an instability arises when simultaneously blowing into two rubber balloons attempting to inflate them both. Only the larger balloon will inflate, because it has a lower internal pressure than the smaller one, and is therefore easier to inflate.

This is what is at play in the selection of germ cells: such pressure differences tend to destabilize the symmetric configuration with equal germ cell volumes, so-called hydraulic instabilities, leading to the growth of the larger germ cell at the expense of the smaller one. By artificially reducing germ cell volumes via thermoviscous pumping (FLUCS method: focused-light-induced cytoplasmic streaming), the team demonstrated that the reduction in cell volumes leads to their extrusion and cell death, indicating that once a cell is below a critical size, apoptosis is induced and the cell dies.

By using confocal imaging, the researchers could image the full organism of the living worm to receive a global and precise picture of the volumes of all the gonad cells, as well as the exchange of fluids between the cells. Stephan Grill, Speaker of the Cluster of Excellence Physics of Life (PoL) and supervisor of the multidisciplinary work, adds These findings are very exciting because they reveal that the life and death decision in the cells is of mechanical nature and related to tissue hydraulics. It helps to understand how the organism auto-selects a cell that will become an egg. Furthermore, the study is another example of the excellent cooperation between biologists, physicists and mathematicians in Dresden.

Reference: A hydraulic instability drives the cell death decision in the nematode germline by Nicolas T. Chartier, Arghyadip Mukherjee, Julia Pfanzelter, Sebastian Frthauer, Ben T. Larson, Anatol W. Fritsch, Rana Amini, Moritz Kreysing, Frank Jlicher and Stephan W. Grill, 20 May 2021, Nature Physics.DOI: 10.1038/s41567-021-01235-x

Cell Biology

Braintale Appoints Industry Leaders Spyros Artavanis-Tsakonas and Nitza Thomasson to Its Board of Directors – BioSpace

June 5, 2021 medical

We welcome both Spyros and Nitza as international recognized leaders in their respective fields who will help us expand our strategic vision and grow Braintale internationally as they deeply understand our science-based approach and the entrepreneur journey said Julie Rachline, CEO. We are thrilled to complement our board with such distinguished experts, and we are looking forward to a fruitful collaboration comments Vincent Perlbarg, president.

Professor Spyros Artavanis-Tsakonas, a molecular biologist and developmental geneticist, is Professor Emeritus in the Department of Cell Biology at Harvard Medical School. He is the founding Director of the Developmental and Regenerative Biology Program at Harvard Medical School. He joined the Yale faculty in 1981 in the Department of Biology and in 1989 was concurrently, Professor at the Department of Cell Biology at the Yale School of Medicine and served as the Director of the Biological Sciences Division at Yale. He was a Howard Hughes Medical Institute Investigator from 1987 to 1998 when he left for Harvard, where he was appointed Professor of Cell Biology. In 1999 he was elected Professor at the Collge de France, in Paris, holding the Chair of Biology and Genetics of Development until 2012 when he became Professeur honoraire. He is the Founding Director of the Department of Genetics and Developmental Biology at Institut Curie, Paris, 2007-2009.

From 2012 to March 2017, he served as Chief Scientific Officer and Executive Vice President at Biogen Inc.

He is a fellow of the American Academy of Arts and Sciences, an associate member of EMBO, and a corresponding member of the Academy of Athens and a member of the Cambridge Philosophical Society. He is the co- founder and President of Fondation Sante a charitable organization supporting Biomedical research in Greece and a co-founder of the Biotechnology companies Exelixis, Cellzome and Anadys.

Dr Nitza Thomasson is the co-founder of Gensight Biologics (Gene therapy for ophthalmologic diseases) and BrainEver (Advanced medicinal products to treat neurodegenerative diseases). After a post doc at Northwestern & Rush University (Chicago, USA), she joined the pharma industry to develop medicines for neurologic and psychiatric disorders at Servier. Then she moved to the biotech world, joining Fovea Pharma in 2009, that became Ophthalmology Division of Sanofi. She contributed to the start of Tissium (2014 - Head of Development), while co-founding GenSight Biologics (2013 - Preclinical and CMC Officer), then BrainEver (2015 - Chief Operating Officer). In 2018, Nitza founded NtzConsulting.

Nitza is also Venture Partner at OmnesCapital. She is board member to support innovation and growth in the healthcare company portfolio.

About Braintale Braintale is an innovative company opening a new era in medicine by providing physicians with clinically validated prognostic solutions for the management of brain injured patients through sensitive and reliable measurements of brain white-matter microstructure alterations. Building on more than 15 years in clinical development, Braintales products are developed collaboratively to address medical need and fulfill expectations of healthcare professionals and patients alike.Since its inception in 2018, the company has set up a complete quality management system and is now ISO :13485 :2016 certified, with a suite of products available on the European market.For more information, please visit http://www.braintale.fr

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005591/en/

Excerpt from:
Braintale Appoints Industry Leaders Spyros Artavanis-Tsakonas and Nitza Thomasson to Its Board of Directors - BioSpace

Cell Biology

Bruker Launches timsTOF trueSCP for Unbiased Single Cell 4D-Proteomics and Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth – Business Wire

June 5, 2021 medical

BILLERICA, Mass.--(BUSINESS WIRE)--At Brukers virtual 4D-Proteomics eXceed Symposium (eXceed Symposia 2021 | Bruker), Bruker Corporation (Nasdaq: BRKR) today announced the launch of two new timsTOF instruments. They further advance and enable new applications and methods in unbiased proteomics, epiproteomics/PTM characterization, and unbiased, deep multiomic biomarker discovery, for example in cancer liquid biopsy research. Brukers collaborators are making major progress in unbiased single cell proteomics, phosphoproteomics and plasma proteomics, leveraging the speed, sensitivity and dynamic range of large-scale CCS-enabled 4D-Proteomics and 4D-Epiproteomics.

At the end of 2020, a breakthrough paper by the Mann-group demonstrated unbiased, true single-cell proteomics on over 1,400 protein groups on a timsTOF R&D prototype to address new quantitative questions in single-cell biology and pathobiology.1 Bruker has accelerated its product development and today launches the ultra-high sensitivity timsTOF trueSCP system for unbiased, quantitative single-cell 4D-Proteomics, and for ultra-sensitive neoantigen discovery in immunopeptidomics.

Since its introduction in 2017, the timsTOF Pro system has offered researchers new capabilities in unbiased CCS-enabled 4D-Proteomics, typically on 5x-20x lower sample amounts and with 3x-5x faster run times for single shot, deep proteomics - with higher throughput and unprecedented robustness.

With the introduction of the next-generation timsTOF Pro 2, Bruker continues the revolution in CCS-enabled 4D-Proteomics, as well as in 4D-Epiproteomics, defined here broadly as the characterization of all protein posttranslational modifications (PTMs). The timsTOF Pro 2 offers deeper proteome coverage of >6,000 protein groups and >60,000 unique peptides in 60 minute gradients on 200 ng HeLa digests. It also achieves good depth of proteome and epiproteome coverage at 10x lower amounts, e.g., with ~4,000 proteins and ~30,000 peptides on 20 ng digests. The outstanding timsTOF Pro 2 sensitivity significantly enhances methods to detect post-translational modificiations (PTMs), such as phosphoproteomics and ubiquitination studies, for CCS-enabled, unbiased, large-scale 4D-Epiproteomics, which is tremendously important in physiology, cell biology and disease biology, especially in cancer.

Bruker also announced new capabilities in PaSER real-time search software for 4D-Proteomics. The new PaSER 2022 offers large-scale CCS-enabled bioinformatics, leveraging the unique tims/PASEF methods. For example, the new TIMScore increases the confidence of peptide IDs by leveraging the fourth dimension of large-scale collision cross sections (CCS) on all measured peptides. Increased confidence using CCS reduces ambiguities of redundant peptide sequences - resulting in more protein group and unique peptide identifications based on the same FDR threshold.

Frank H. Laukien, Bruker President and CEO, commented: I believe that the timsTOF trueSCP is a revolutionary new tool for unbiased, deep and quantitative single-cell biology that is complementary to scRNA-seq. In the future, basic research in single-cell biology and pathogenesis will greatly benefit from having both eyes open in gene expression, by combining transcriptomics with unbiased, deep and quantitative proteomics and epiproteomics data for multiomic biomarker panels.

Dr. Laukien continued: In liquid biopsies there is an unmet clinical need for greater cancer stage I/II detection sensitivity and improved positive predictive values, as well as for earlier detection of therapy resistance. For integrated multiomic deep learning in both, cancer cell genomics and epiproteomics, as well as in host immune response and tumor microenvironment, unbiased proteomics and PTMs are highly complementary to NGS for achieving further major progress in PPV for the benefit of patients.

A. timsTOF trueSCP Launch

The timsTOF trueSCP is the culmination of a collaboration with the laboratory of Professor Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried, Germany, and with Evosep on new Whisper methods at ultra-low flow rates of ~100 nL/min.

The timsTOF trueSCP achieves 5 times higher ion transmission for data-independent dia-PASEF, or parallel reaction monitoring prm-PASEF methods. The dia-PASEF 2 method has demonstrated true, unbiased 4D-Proteomics from single cells 1 with quantitation of ~1,500 proteins/cell, in hundreds of isolated single cells ex situ, in combination with the Evosep One LC with Whisper. The timsTOF trueSCP is a dedicated ultra-high sensitivity instrument for unbiased single cell proteomics, after laser capture microdissection of one or a few cells, as well as for ultra-sensitive neoantigen discovery in immunopeptidomics in the field of immunooncology research. With the timsTOF trueSCP, a system is now available to expand the single-cell biology horizons beyond genomics and transcriptomics to unbiased, quantitative 4D-Proteomics.

Quantitative biology can now be done also with unbiased single cell proteomics, as cells at different stages in the growth cycle have a protein core with sufficient copy numbers to observe statistically relevant changes in abundance, when compared to sparse mRNA copy numbers.

Professor Matthias Mann commented: I always said that single cell proteomics would not happen in my lifetime, but Im happy to have been proven wrong. Single-cell technologies are revolutionizing biology but are today mainly limited to imaging and deep sequencing. However, proteins are the main drivers of cellular function and in-depth characterization of individual cells by mass spectrometry (MS)-based proteomics using instrumentation like the timsTOF trueSCP will be highly complementary. Our laboratory has been very pleased with the collaboration with Bruker, and I congratulate the Bruker team on the rapid commercialization of the novel timsTOF trueSCP technology.

B. Next-generation timsTOF Pro 2 Launch

The timsTOF Pro 2 is the new proteomics workhorse for robust, unbiased, deep and quantitative 4D-Proteomics and 4D-Epiproteomics for plasma, tissue samples and from cell cultures. Further design advances combined with enhanced dda-PASEF, dia-PASEF and prm-PASEF methods deliver industry-leading performance, with unparalleled robustness and throughput. The timsTOF Pro 2 allows the detection of > 6,000 proteins and > 60,000 peptides by dda-PASEF with 60 minute gradients on 200 ng of digest. It also has new high sensitivity methods that enable very good proteome coverage with 10x less digest, down to 20 ng, for >3,500 protein groups and >25,000 unique peptides using a 30 minute gradient. dia-PASEF workflows on timsTOF Pro 2 include an improved interface for designing experiments, and can now identify ~8,000 protein groups and 70,000 peptides in 60 minutes on 200 ng of digests.

These timsTOF Pro 2 performance improvements are important for 4D-Epiproteomics, and particularly phosphoproteomics. Phosphorylation is key to signaling and is often mis-regulated in cancer and other diseases. Phosphopeptides are enriched prior to analysis, and researchers often started with several milligrams of biological material to isolate a sufficient quantity of phosphopeptides for analysis. As shown by Professor Stefan Tenzer at the Institute for Immunology of the University Medical Center of the Johannes-Gutenberg University Mainz, with the timsTOF Pro 2 it is now possible to start from just 150 ug of protein and identify 27,768 unique phosphopeptides. In particular, 457 co-eluting positional phosphorylation isomers were resolved by the combination of TIMS and PASEF. Even with 25 ug of protein, >4,400 phosphopeptides can be reproducibly identified, paving the way toward phosphoproteomics on needle biopsies.

Professor Tenzer stated: Besides its high sensitivity, a unique aspect of the TIMS technology is its capability to resolve positional phosphorylation isomers in the gas phase by ion mobility, thus providing more detailed insights into signaling pathways.

Sensitivity is absolutely crucial in immunopeptidomics, and Professor Janne Lehti of the Science for Life Laboratory, Department of Oncology-Pathology at the Karolinska Institute in Stockholm, Sweden, added: We have been impressed with the performance of the timsTOF Pro. In particular, the speed and sensitivity of the instrument enable us to see more immunopeptides from limited amounts of starting material, which we expect to be particularly valuable for neoantigen discovery and the development of personalized therapies for cancer immunooncology treatments.

C. New PaSER Capabilities

New functionalities of PaSER 2022 include: MOMA Viewer, real-time de novo peptide sequencing and TIMScore for unbiased 4D-Proteomics, in addition to Run & Done search.

Sebastian Vaca, PhD, Research Scientist in the Carr Lab at the Broad Institute of MIT and Harvard, explained: Real-time results by PaSER on our timsTOF Pro have been a huge time saver. They allows us to develop methods faster, inform on LC and instrument performance, and provide a major gain in the efficiency of proteomics and PTM research.

PaSER now has a MOMA (mobility offset mass aligned) viewer to characterize co-eluting isomeric or isobaric ions by large-scale CCS. The GPU-based search has been extended into immunoproteomics. Working with Professor Tony Purcell and Bioinformatics Solutions Inc., the ability to perform real-time de novo sequence assignment delivers new capabilities for novel neoantigen discovery.

Finally, PaSER 2022 incorporates a new CCS-enabled database search algorithm, called TIMScore, developed together with Professor John Yates, and driven by machine learning. TIMScore becomes the first fundamentally CCS-enabled database search algorithm, increasing the number of protein and peptides identified, while maintaining FDR control and real-time search speeds.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Brukers high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: http://www.bruker.com.

More here:
Bruker Launches timsTOF trueSCP for Unbiased Single Cell 4D-Proteomics and Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth - Business Wire

Cell Biology

Cloud Computing in Cell Biology, Genomics and Drug Development Market Global Demand, Research and Top Leading Player to 2026 Covid-19 Analysis KSU |…

June 5, 2021 medical

Cloud Computing in Cell Biology, Genomics Drug Development Market Report defines the business objective to help business owners to avoid contradictory expectations. It provides you customer data along with their demands hence you can accordingly plan for the launching of the product in the market. It presents all the data about whole market scenario. With the help of prominent data provided in the Cloud Computing in Cell Biology, Genomics Drug Development Market Report, organizations come to know about customers completely and can achieve their goal of selling products in huge quantity and getting huge profits too. Clearly setting the business goal at the beginning will surely help to avoid getting difficulties and set the business easily.

Request sample copy of this report at

https://www.researchforetell.com/reports/68629/cloud-computing-in-cell-biology-genomics-and-drug-development-marketglobal-outlook-and-forecast-2021-2027/request

The scope of this research report extends from the basic outline of the Cloud Computing in Cell Biology, Genomics Drug Development Market to tricky structures, classifications and applications. This research report also provides a clear picture of the global market by presenting data through effective information graphics. It also provides a detailed list of factors that affect market growth.

A detailed study of the competitive landscape of the Global Cloud Computing in Cell Biology, Genomics Drug Development Market has been given along with the insights of the companies, financial status, trending developments, mergers & acquisitions and SWOT analysis. This research will give a clear and precise idea about the overall market to the readers to take beneficial decisions.

Cloud Computing in Cell Biology, Genomics Drug Development Market Report provides future growth drivers and competitive landscape. This will be beneficial for buyers of the market report to gain a clear view of the important growth and subsequent market strategy. The granular information in the market will help monitor future profitability and make important decisions for growth.

Inquire for a discount at

https://www.researchforetell.com/reports/68629/cloud-computing-in-cell-biology-genomics-and-drug-development-marketglobal-outlook-and-forecast-2021-2027/discount

This report contains market size and forecasts of Cloud Computing in Cell Biology, Genomics and Drug Development in Global, including the following market information:

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Cloud Computing in Cell Biology, Genomics and Drug Development market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cloud Computing in Cell Biology, Genomics and Drug Development companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market Segment Percentages, By Type, 2020 (%)

Public Cloud

Private Cloud

Hybrid Cloud

China Cloud Computing in Cell Biology, Genomics and Drug Development Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Cloud Computing in Cell Biology, Genomics and Drug Development Market Segment Percentages, By Application, 2020 (%)

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Clinical Laboratories

Hospitals and Research Institutes

Others

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market Segment Percentages, By Region and Country, 2020 (%)

North America

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Cloud Computing in Cell Biology, Genomics and Drug Development Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Cloud Computing in Cell Biology, Genomics and Drug Development Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

Google Inc.

Amazon Web Services, Inc.

IBM Corp.

Oracle Corporation

Microsoft Corp.

Arisglobal

Benchling

Box Inc

Cisco Systems

Dell Emc

Cognizant

Dincloud

Exponential-e

Informatica

Key Features of the Report:

Complete report is available at

https://www.researchforetell.com/reports/68629/cloud-computing-in-cell-biology-genomics-and-drug-development-marketglobal-outlook-and-forecast-2021-2027

There are 10 Chapters to deeply display the Cloud Computing in Cell Biology, Genomics Drug Development Market.

Chapter 1 to analyze the top manufacturers of Cloud Computing in Cell Biology, Genomics Drug Development, with sales, revenue and price of Cloud Computing in Cell Biology, Genomics Drug Development in 2021-2027.

Chapter 2, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2021-2027.

Chapter 3, to show the global market by regions, with sales, revenue and market share of Cloud Computing in Cell Biology, Genomics Drug Development, for each region, from 2021-2027.

Chapter 4, 5, 6 and 7 to analyze the key regions, with sales, revenue and market share by key countries in these regions.

Chapter 8 and 9, to show the market by type and application, with sales market share and growth rate by type, application, from 2021-2027.

Chapter 10 Cloud Computing in Cell Biology, Genomics Drug Development Market forecast, by regions, type and application, with sales and revenue, from 2021-2027.

About Us

Research Foretell is an information service company that provides market research, custom, and consulting services. Decision-making is complicated and we help you to solve your biggest puzzle, by identifying, analyzing, and monitoring the recent developing technologies and markets. Research Foretell is always forefront on classifying new opportunity in the market; with us you always have the first mover advantage.

Robert Claussen (Head of Sales)

Phone: +91-81499-24059

Email: sales@researchforetell.com

The rest is here:
Cloud Computing in Cell Biology, Genomics and Drug Development Market Global Demand, Research and Top Leading Player to 2026 Covid-19 Analysis KSU |...

Cell Biology

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market 2021 Briefing, Trends, Applications, Types, Research, Forecast To 2026 …

June 5, 2021 medical

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market 2021 by Company, Regions, Type and Application, Forecast to 2026 presents a meticulous investigation of the current scenario of the market that contains wide-ranging industry information. The report throws light on dedicated references and the strategic functionality of various global market elements. The report explores practical growth strategies and recommendations related to the global Cloud Computing in Cell Biology, Genomics and Drug Development industry. It also contains helpful and important facts and figures, expert opinions, and the latest developments across the globe. To calculate the global market size, the report considers the revenue generated from the sales of Cloud Computing in Cell Biology, Genomics and Drug Development globally.

The report helps readers gauge future-specific growth probabilities, along with a thorough evaluation of primary growth initiators and focused elements that augment growth revenue generation, aligning with appropriate growth objectives. It highlights exclusive and relevant factors related to this market. Key players in global and major regions are assessed and the market is classified by product and application/end industries. The report throws light on multiple sections of the report including the global Cloud Computing in Cell Biology, Genomics and Drug Development market size and forecast, drivers, challenges, trends, and more.

NOTE: COVID-19 has had a major impact on the world economy in addition to that on the public health. This particular pandemic had caused severe economic destruction and not a single country has been left unaffected. The virus has forced businesses around the globe to change the way they operate. This report gives an analysis of the COVID-19 aftermath on Cloud Computing in Cell Biology, Genomics and Drug Development market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/187077

In this comprehensive report, the competitive landscape is analyzed in terms of markets, applications, and geographies. The competitive analysis helps the vendors know their capabilities and opportunities for future growth prospects. The report then incorporates a thorough assessment of market participation showcased by inquisitive market players, followed by an assessment of their overall footing in the competitive landscape. The global Cloud Computing in Cell Biology, Genomics and Drug Development industry size is defined and forecasted with respect to type, application, and region.

The top players listed in the market report are:

Based on type, the report split into:

Based on application market is segmented into:

Market segmentation, by regions:

Important Figures Measured In This Report:

The report incorporates financial implications of various developments comprising production and consumption patterns. Expert research opinion also ensures that the growth delay is a significant concern which is further believed to demonstrate suitable indication in the upcoming times as well. Moreover, vendors successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies are highlighted in the global Cloud Computing in Cell Biology, Genomics and Drug Development report to help them execute further business expansion and growth.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/187077/global-cloud-computing-in-cell-biology-genomics-and-drug-development-market-2021-by-company-regions-type-and-application-forecast-to-2026

Highlights of The Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Cell Biology

Novo Nordisk partners with Heartseed on heart failure cell therapy – PMLiVE

June 5, 2021 medical

Danish pharma company Novo Nordisk has announced a new collaboration and licence agreement with Japans Heartseed to develop the companys investigational cell therapy HS-001 for heart failure.

HS-001, Heartseeds lead asset, is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC). The therapy is currently being developed as a treatment for heart failure.

Heartseed is already planning to launch a phase 1/2 study of HS-001 in Japan in the second half of 2021, which will evaluate the safety and efficacy of the therapy for the treatment of heart failure caused by ischaemic heart disease.

Under the terms of their agreement, Novo Nordisk will gain exclusive rights to develop, manufacture and commercialise HS-001 globally, excluding Japan where Heartseed will retain the rights to solely develop the therapy.

However, Novo Nordisk has the rights to co-commercialise HS-001 with Heartseed in Japan, with equal profit and cost sharing.

In return, Heartseed is eligible to receive up to a total $598m, with $55m earmarked in upfront and near-term milestone payments.

The Japanese biotech company is also eligible to receive tiered high single-digit to low double-digit royalties of annual net sales on the product outside Japan.

"We are delighted to have a company with the expertise and resources of Novo Nordisk as our partner for development and commercialisation of HS-001, and are also honoured that Novo Nordisk has recognised the innovativeness and high potential of our technology," said Keiichi Fukuda, chief executive officer of Heartseed.

"We believe that the partnership with Novo Nordisk is very valuable as we seek to disseminate our Japan-origin innovation globally as early as possible, he added.

Through this important collaboration with Heartseed, we aim to pioneer novel treatment solutions for people with cardiovascular disease, said Marcus Schindler, chief scientific officer, EVP research and early development at Novo Nordisk.

We [will] gain access to an innovative clinical asset, underlying technology and deep expertise within the field of iPSC biology and cardiac cell transplantation, which can be combined with our knowledge and capabilities in stem cell biology and manufacturing, he added.

Read the original here:
Novo Nordisk partners with Heartseed on heart failure cell therapy - PMLiVE